Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
Demo Company
PURITAN MEDICAL

X-Ray Imaging System Enables Scientists to See in Real Time How Effective Treatments are for Cystic Fibrosis

By BiotechDaily International staff writers
Posted on 25 Aug 2014
Image: Dr. Kaye Morgan, Monash University (Photo courtesy of Monash University).
Image: Dr. Kaye Morgan, Monash University (Photo courtesy of Monash University).
A new imaging approach allows researchers to monitor the effectiveness of a treatment for the life-threatening genetic disorder.

Cystic fibrosis affects many of the body’s systems, but most severely the lungs, and currently it can take several months to measure how effective treatment is for the early-fatal lung disease.

Dr. Kaye Morgan, from Monash University (Melbourne; VIC, Australia), and lead researcher of the study, reported that the new X-ray imaging strategy allows researchers to visualize soft tissue structures, for example, the airways, brain, and lungs, which are effectively hidden in standard X-ray images. “At the moment we typically need to wait for a cystic fibrosis treatment to have an effect on lung health, measured by either a lung CT [computed tomography] scan or breath measurement, to see how effective that treatment is,” Dr. Morgan said. “However the new imaging technique allows us for the first time to noninvasively see how the treatment is working ‘live’ on the airway surface.”

Dr. Morgan noted that this X-ray imaging method would enable clinicians and researchers to measure how effective treatments are, and progress new treatments to the clinic at a much quicker rate, a key goal of the investigators. “Because we will be able to see how effectively treatments are working straight away, we’ll be able to develop new treatments a lot more quickly, and help better treat people with cystic fibrosis,” Dr. Morgan said.

Dr. Morgan noted that the new imaging technology, which was developed using a synchrotron X-ray source, may also create new avenues for assessing how effective treatments were for other lung, heart, and brain diseases.

The study’s findings were published August 15, 2014, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

Monash University



Channels

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.